Who is sponsoring NCT02468674?

NCT02468674 is sponsored by Novartis Pharmaceuticals.

What condition does NCT02468674 study?

NCT02468674 studies Sarcopenia.

What drugs are being tested in NCT02468674?

Interventions: bimagrumab, Placebo.

What is the status of NCT02468674?

NCT02468674 is currently COMPLETED.

Last reviewed 2020-06-16 · How we verify

A 24-week Off-drug Extension Study in Sarcopenic Elderly Who Completed Treatment in the 6-month Core Study

NCT02468674 PHASE2 COMPLETED Results posted

This extension study was a 24-week off-drug follow-up of the core CBYM338E2202 (NCT ) study and the main objective was to determine the long-term durability of bimagrumab (BYM338) effect after a 6-month treatment period.

Details

Lead sponsor	Novartis Pharmaceuticals
Phase	PHASE2
Status	COMPLETED
Enrolment	160
Start date	Wed Jul 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Dec 03 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Sarcopenia

Interventions

bimagrumab
Placebo

Countries

Denmark, France, Japan, Russia, Belgium, Taiwan, South Korea, Switzerland, Australia, United States, Spain, Czechia